Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech Files Investigational New Drug Application to Begin Phase 1/2 Trial of New Drug Candidate for Eczema
Jan 12, 2005
|
70.8 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Jan 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that the company filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to begin a Phase1/2 clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment ...
|
|
|
Corgentech to Present at 23rd Annual JPMorgan Healthcare Conference
Jan 5, 2005
|
63.4 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Jan 05, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 23rd Annual JPMorgan Healthcare Conference on Wednesday, January 12, 2005, at 11:00 a.m. Pacific St...
|
|
|
Corgentech and Bristol-Myers Squibb Announce Results From Edifoligide (E2F Decoy) Phase 3 Trial for Peripheral Bypass Graft
Dec 6, 2004
|
57.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced top-line results from the first of two Phase 3 clinical trials for edifoligide (E2F Decoy) an investigational product to treat vein graft failure of the h...
|
|
|
Corgentech to Host Webcast Conference Call on Monday, December 6, 2004
Dec 3, 2004
|
69.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Dec 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) will host a webcast teleconference Monday, December 6, 2004 at 8:30 a.m. Eastern Time to review top-line results from PREVENT III, a Phase 3 clinical trial testing edifoligide (E2F Decoy) for the treatment of peripheral artery bypass graft...
|
|
|
Corgentech to Present at Credit Suisse First Boston Annual Healthcare Conference
Nov 12, 2004
|
64.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Nov 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Credit Suisse First Boston Annual Healthcare Conference on Thursday, November 18, 2004 at 4:30 p.m...
|
|
|
Click here to download our most recent fact sheet.